Vareniclin - Erhöhtes kardiovaskuläres risiko bei der raucherentwöhnung?

Research output: Contribution to journalResearch articleContributedpeer-review


  • M. Dewenter - , University of Göttingen (Author)
  • A. El-Armouche - , University of Göttingen (Author)


Smoking is one of the most important cardiovascular risk factors. Varenicline, a partial agonist of the α 4β 2 nicotinic acetylcholine receptor, has been demonstrated to be the most efficacious medication for smoking cessation. However, treatment with varenicline has sometimes been associated with severe cardiovascular side effects. This article discusses the current data with respect to the cardiovascular safety of varenicline therapy.

Translated title of the contribution
Varenicline - Increased cardiovascular risk in smoking cessation?


Original languageGerman
Pages (from-to)240-243
Number of pages4
JournalDer Kardiologe : die Fortbildungszeitschrift der Deutschen Gesellschaft für Kardiologie, Herz- und Kreislaufforschung
Issue number3
Publication statusPublished - Jun 2012
Externally publishedYes

External IDs

ORCID /0000-0003-2514-9429/work/151982637



  • Cardiovascular risk, Nicotine dependence, Nicotine receptor partial agonist, Smoking cessation, Varenicline